Don M. Benson - Concepedia

Author

Don M. Benson

Also Known As

Allen, Steven L., D M Benson, DON M. BENSON, DON M. BENSON, Don Benson, Don M Benson, Don M Benson Jr, Don M. Benson, Don M. Benson Jr., Don M. Benson,

324

Publications

8.6K

Citations

H-Index

124

Concepts

All Affiliations

The Ohio State University Washington University in St. Louis The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Dana-Farber Cancer Institute Cornell University

About

Don M. Benson is an author at The Ohio State University specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	42	2.4K
2	Health Sciences	10	10	266
3	Social Sciences	3	3	68
4	Humanities	1	1	18
5	Public Health	1	1	10

Don M. Benson

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody Don M. Benson, Courtney E. Bakan, Anjali Mishra, Blood	2010	797
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia Jennifer R. Brown, John C. Byrd, Steven Coutré, Blood	2014	583
RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development Flavia Pichiorri, Sung-Suk Suh, Alberto Rocci, Cancer Cell Hematological MalignancyTumor BiologyP53/mdm2 Autoregulatory LoopMedicineMultiple Myeloma Development	2010	443
Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells François Romagné, Pascale André, Pieter Spee, Blood	2009	388
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC Shauna M. Collins, Courtney E. Bakan, Gina D. Swartzel, Cancer Immunology Immunotherapy Hematological MalignancyCancer ImmunosurveillanceImmunologyImmune Checkpoint InhibitorCs1 Ligation	2013	291
The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector Wenjuan Dong, Xiaojin Wu, Shoubao Ma, Cancer Discovery	2019	288
Pro- and Antiinflammatory Cytokine Signaling: Reciprocal Antagonism Regulates Interferon-gamma Production by Human Natural Killer Cells Jianhua Yu, Wei Min, Brian Becknell, Immunity InflammationCytokineInterferon-gamma ProductionAutoimmune DiseaseInnate Immune System	2006	274
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL) Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman, Blood	2014	247
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma Don M. Benson, Craig C. Hofmeister, Attaya Suvannasankha, Blood	2012	236
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma Ian W. Flinn, Brad S. Kahl, John P. Leonard, Blood	2014	206

Page 1